Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Y Tian, D Xie, L Yang - Signal transduction and targeted therapy, 2022 - nature.com
Oncolytic viruses (OVs) are emerging as potentially useful platforms in treatment methods for
patients with tumors. They preferentially target and kill tumor cells, leaving healthy cells …
patients with tumors. They preferentially target and kill tumor cells, leaving healthy cells …
Exhaustion of CAR T cells: potential causes and solutions
T Kouro, H Himuro, T Sasada - Journal of Translational Medicine, 2022 - Springer
Chimeric antigen receptor (CAR) T cell therapy has attracted attention for its promising
therapeutic effects on hematological malignancies. However, there are problems such as …
therapeutic effects on hematological malignancies. However, there are problems such as …
Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma
D Martínez Bedoya, V Dutoit, D Migliorini - Frontiers in immunology, 2021 - frontiersin.org
Chimeric antigen receptor (CAR) T cell therapy has emerged as one of the major
breakthroughs in cancer immunotherapy in the last decade. Outstanding results in …
breakthroughs in cancer immunotherapy in the last decade. Outstanding results in …
IL-7: comprehensive review
Overview IL-7 is a member of the family of cytokines with four anti-parallel α helixes that bind
Type I cytokine receptors. It is produced by stromal cells and is required for development …
Type I cytokine receptors. It is produced by stromal cells and is required for development …
Tumor buster-where will the CAR-T cell therapy 'missile'go?
Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing
technology represents a significant breakthrough in personalized immunotherapy for human …
technology represents a significant breakthrough in personalized immunotherapy for human …
Leveraging NKG2D ligands in immuno-oncology
Immune checkpoint inhibitors (ICI) revolutionized the field of immuno-oncology and opened
new avenues towards the development of novel assets to achieve durable immune control …
new avenues towards the development of novel assets to achieve durable immune control …
[HTML][HTML] Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies
ZZ Zhang, T Wang, XF Wang, YQ Zhang… - Pharmacological …, 2022 - Elsevier
Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that
has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma …
has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma …
[HTML][HTML] Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy
I Wang, L Song, BY Wang, AR Kalebasty… - American journal of …, 2022 - ncbi.nlm.nih.gov
Immunotherapy remains to be an appealing treatment option for prostate cancer with some
documented promise. Prostate cancer is traditionally considered as an immunologically …
documented promise. Prostate cancer is traditionally considered as an immunologically …
Emerging strategies in TCR-engineered T cells
Immunotherapy of cancer has made tremendous progress in recent years, as demonstrated
by the remarkable clinical responses obtained from adoptive cell transfer (ACT) of patient …
by the remarkable clinical responses obtained from adoptive cell transfer (ACT) of patient …
CAR T cells: Building on the CD19 paradigm
A Globerson Levin, I Rivière, Z Eshhar… - European journal of …, 2021 - Wiley Online Library
Spearheaded by the therapeutic use of chimeric antigen receptors (CARs) targeting CD19,
synthetic immunology has entered the clinical arena. CARs are recombinant receptors for …
synthetic immunology has entered the clinical arena. CARs are recombinant receptors for …